Back to Search Start Over

Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project)

Authors :
Christopher P, Millward
Terri S, Armstrong
Heather, Barrington
Sabrina, Bell
Andrew R, Brodbelt
Helen, Bulbeck
Anna, Crofton
Linda, Dirven
Theo, Georgious
Paul L, Grundy
Abdurrahman I, Islim
Mohsen, Javadpour
Sumirat M, Keshwara
Shelli D, Koszdin
Anthony G, Marson
Michael W, McDermott
Torstein R, Meling
Kathy, Oliver
Puneet, Plaha
Matthias, Preusser
Thomas, Santarius
Nisaharan, Srikandarajah
Martin J B, Taphoorn
Carole, Turner
Colin, Watts
Michael, Weller
Paula R, Williamson
Gelareh, Zadeh
Amir H, Zamanipoor Najafabadi
Michael D, Jenkinson
Viktor, Zherebitskiy
Neurology
Source :
BMJ Open, 12(5). BMJ PUBLISHING GROUP, BMJ Open, 12(5). BMJ Publishing Group, BMJ open, vol 12, iss 5
Publication Year :
2022

Abstract

IntroductionMeningioma is the most common primary intracranial tumour in adults. The majority are non-malignant, but a proportion behave more aggressively. Incidental/minimally symptomatic meningioma are often managed by serial imaging. Symptomatic meningioma, those that threaten neurovascular structures, or demonstrate radiological growth, are usually resected as first-line management strategy. For patients in poor clinical condition, or with inoperable, residual or recurrent disease, radiotherapy is often used as primary or adjuvant treatment. Effective pharmacotherapy treatments do not currently exist. There is heterogeneity in the outcomes measured and reported in meningioma clinical studies. Two ‘Core Outcome Sets’ (COS) will be developed: (COSMIC: Intervention) for use in meningioma clinical effectiveness trials and (COSMIC: Observation) for use in clinical studies of incidental/untreated meningioma.Methods and analysisTwo systematic literature reviews and trial registry searches will identify outcomes measured and reported in published and ongoing (1) meningioma clinical effectiveness trials, and (2) clinical studies of incidental/untreated meningioma. Outcomes include those that are clinician reported, patient reported, caregiver reported and based on objective tests (eg, neurocognitive tests), as well as measures of progression and survival. Outcomes will be deduplicated and categorised to generate two long lists. The two long lists will be prioritised through two, two-round, international, modified eDelphi surveys including patients with meningioma, healthcare professionals, researchers and those in caring/supporting roles. The two final COS will be ratified through two 1-day online consensus meetings, with representation from all stakeholder groups.Ethics and disseminationInstitutional review board (University of Liverpool) approval was obtained for the conduct of this study. Participant eConsent will be obtained prior to participation in the eDelphi surveys and consensus meetings. The two systematic literature reviews and two final COS will be published and freely available.Trial registration numberCOMET study ID 1508

Details

Language :
English
ISSN :
20446055
Volume :
12
Issue :
5
Database :
OpenAIRE
Journal :
BMJ Open
Accession number :
edsair.doi.dedup.....433e4a5e5d548f38a272efcff4b62290